Fragment-based Drug Design Using NMR Methods

Fragment-based drug design (FBDD) has evolved from a novel approach in the search of new hits to a valuable alternative to high-throughput screening (HTS) campaigns of many pharmaceutical companies. The increasing relevance of FBDD in the drug discovery area has been concomitant with the implementation of biophysical techniques used for the detection of weak inhibitors. In particular, NMR presents clear advantages over other techniques used in drug discovery as it can be used in the 3-D characterization of protein targets and protein–ligand complexes, as well as in the hit identification and lead optimization phases. Herein, we review the potential of FBDD by NMR using either target- or ligand-based methods in the discovery of novel fragment blocks against pharmaceutically relevant protein targets, and the different follow-up design strategies used to convert a fragment hit into a lead. Keywords: fragment-based screening; high-throughput screening; NMR spectroscopy; druggability; library design; fragment prioritization; fragment optimization; clinical candidate; drug development

[1]  Niklas Blomberg,et al.  Design of compound libraries for fragment screening , 2009, J. Comput. Aided Mol. Des..

[2]  Claudio Dalvit,et al.  Ligand- and substrate-based 19F NMR screening: Principles and applications to drug discovery , 2007 .

[3]  W. Jahnke,et al.  Ranking of high-affinity ligands by NMR spectroscopy. , 2009, Angewandte Chemie.

[4]  L. Poppe,et al.  Fragment based drug discovery: practical implementation based on ¹⁹F NMR spectroscopy. , 2012, Journal of medicinal chemistry.

[5]  Chris Abell,et al.  A three-stage biophysical screening cascade for fragment-based drug discovery , 2013, Nature Protocols.

[6]  Christian Ludwig,et al.  SALMON: solvent accessibility, ligand binding, and mapping of ligand orientation by NMR spectroscopy. , 2008, Journal of medicinal chemistry.

[7]  Thomas Peters,et al.  NMR spectroscopy techniques for screening and identifying ligand binding to protein receptors. , 2003, Angewandte Chemie.

[8]  R. Powers.  Advances in nuclear magnetic resonance for drug discovery , 2009, Expert opinion on drug discovery.

[9]  P. Hajduk,et al.  Druggability indices for protein targets derived from NMR-based screening data. , 2005, Journal of medicinal chemistry.

[10]  Christopher A Lepre,et al.  Practical aspects of NMR-based fragment screening. , 2011, Methods in enzymology.

[11]  Rutger H A Folmer,et al.  Fragment screening to predict druggability (ligandability) and lead discovery success. , 2011, Drug discovery today.

[12]  M. Congreve,et al.  Recent developments in fragment-based drug discovery. , 2008, Journal of medicinal chemistry.

[13]  Horst Kessler,et al.  NMR-based screening: a powerful tool in fragment-based drug discovery. , 2007 .

[14]  Monya Baker,et al.  Fragment-based lead discovery grows up , 2012, Nature Reviews Drug Discovery.

[15]  Brett A Tounge,et al.  Ligand efficiency and fragment-based drug discovery. , 2009, Drug discovery today.

[16]  Andrew Pannifer,et al.  Using fragment-based technologies to target protein-protein interactions. , 2012, Current pharmaceutical design.

[17]  P. Hajduk,et al.  A decade of fragment-based drug design: strategic advances and lessons learned , 2007, Nature Reviews Drug Discovery.

[18]  Jeffrey W. Peng,et al.  Theory and applications of NMR-based screening in pharmaceutical research. , 2004, Chemical reviews.

[19]  Gianni Chessari,et al.  From fragment to clinical candidate--a historical perspective. , 2009, Drug discovery today.

[20]  P. Hajduk,et al.  SOS-NMR: a saturation transfer NMR-based method for determining the structures of protein-ligand complexes. , 2004, Journal of the American Chemical Society.

[21]  Wolfgang Jahnke,et al.  Second-site NMR screening and linker design. , 2003, Current topics in medicinal chemistry.

[22]  B. Volkman,et al.  Binding site identification and structure determination of protein-ligand complexes by NMR a semiautomated approach. , 2011, Methods in enzymology.

[23]  K. Gehring,et al.  Ligand specificity in fragment-based drug design. , 2010, Journal of medicinal chemistry.

[24]  Robert Powers,et al.  Estimating protein-ligand binding affinity using high-throughput screening by NMR. , 2008, Journal of combinatorial chemistry.

[25]  Kazuki Ohno,et al.  Two 'Golden Ratio' indices in fragment-based drug discovery. , 2009, Drug discovery today.

[26]  W. Jahnke,et al.  Protein NMR in biomedical research , 2004, Cellular and Molecular Life Sciences CMLS.

[27]  Rafael Gozalbes,et al.  Contributions of computational chemistry and biophysical techniques to fragment-based drug discovery. , 2010, Current medicinal chemistry.

[28]  M. Goldflam,et al.  Computer-Aided Design of Fragment Mixtures for NMR-Based Screening , 2013, PloS one.

[29]  D. Wyss,et al.  Effective progression of nuclear magnetic resonance-detected fragment hits. , 2011, Methods in enzymology.

[30]  Brian K. Shoichet,et al.  Increasing Chemical Space Coverage by Combining Empirical and Computational Fragment Screens , 2014, ACS chemical biology.

[31]  Jan Schultz,et al.  Integration of fragment screening and library design. , 2007, Drug discovery today.

[32]  Edgar Jacoby,et al.  Library design for fragment based screening. , 2005, Current topics in medicinal chemistry.

[33]  Brian L Claus,et al.  Protein-ligand NOE matching: a high-throughput method for binding pose evaluation that does not require protein NMR resonance assignments. , 2006, Journal of the American Chemical Society.

[34]  Claudio Dalvit,et al.  NMR screening techniques in drug discovery and drug design , 2002 .